NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Immunocore Ltd
Erasca, Inc.
Shanghai Juncell Therapeutics
AstraZeneca
Linnaeus Therapeutics, Inc.
American Regent, Inc.